Alendronic Acid

  • #LGM Pharma is a Alendronic Acid CAS# 66376-36-1 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 66376-36-1
  • AHFC code:
  • Synonyms: (4-Amino-1-hydroxybutylidene)bisphosphonic acid, 4-Amino-1-hydroxybutylidene-1,1-bis(phosphonic acid), 4-Amino-1-hydroxybutylidene-1,1-bisphosphonate, Acide alendronique, Acide alendronique [INN-French], Acido alendronico, Acido alendronico [INN-Spanish], Acidum alendronicum, Acidum alendronicum [INN-Latin], Alendronate, Alendronic acid, Arendal, HSDB 7990, MK 217, UNII-X1J18R4W8P
  • ATC Code:
  • Chemical Formula: C4-H13-N-O7-P2
  • Molecular Weight: 249.0947
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB00630
  • SMILES: C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN
  • InChl: 1S/C4H13NO7P2/c5-3-1-2-4(6,13(7,8)9)14(10,11)12/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12)
  • PubChem:
  • IUPAC: (4-Amino-1-hydroxybutylidene)diphosphonic acid Phosphonic acid, (4-amino-1-hydroxybutylidene)bis-

Additional Details

Indication:
For the treatment and prevention of osteoporosis in women and Paget's disease of bone in both men and women.
Pharmacodynamics:
Alendronate, a second-generation bisphosphonate is the first member of a group of drugs which strengthens bone. Alendronate is used to reduce hypercalcemia in tumor-induced bone disease, to treat corticosteroid-induced osteoporosis and Paget's disease, and to prevent osteoporosis in postmenopausal women.
Mode of Action:
The action of Alendronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Alendronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting FPP synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.
Metabolism:
There is no evidence that alendronate is metabolized in humans or animals.
Toxicity:
Alendronate can damage the esophagus both by toxicity from the medication itself and by nonspecific irritation secondary to contact between the pill and the esophageal mucosa, similar to other cases of "pill esophagitis."
General Reference:
Russell RG, Watts NB, Ebetino FH, Rogers MJ: Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008 Jun;19(6):733-59. Pubmed
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials